Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2017 Nov;5(11):887-897.
doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13.
Maria Masulli 2, Antonio Nicolucci 3, Enzo Bonora 4, Stefano Del Prato 5, Aldo P Maggioni 6, Angela A Rivellese 2, Sebastiano Squatrito 7, Carlo B Giorda 8, Giorgio Sesti 9, Paolo Mocarelli 10, Giuseppe Lucisano 3, Michele Sacco 3, Stefano Signorini 10, Fabrizio Cappellini 10, Gabriele Perriello 11, Anna Carla Babini 12, Annunziata Lapolla 13, Giovanna Gregori 14, Carla Giordano 15, Laura Corsi 16, Raffaella Buzzetti 17, Gennaro Clemente 18, Graziano Di Cianni 19, Rossella Iannarelli 20, Renzo Cordera 21, Olga La Macchia 22, Chiara Zamboni 23, Cristiana Scaranna 24, Massimo Boemi 25, Ciro Iovine 26, Davide Lauro 27, Sergio Leotta 28, Elisabetta Dall'Aglio 29, Emanuela Cannarsa 30, Laura Tonutti 31, Giuseppe Pugliese 32, Antonio C Bossi 33, Roberto Anichini 34, Francesco Dotta 35, Antonino Di Benedetto 36, Giuseppe Citro 37, Daniela Antenucci 38, Lucia Ricci 39, Francesco Giorgino 40, Costanza Santini 41, Agostino Gnasso 42, Salvatore De Cosmo 43, Donatella Zavaroni 44, Monica Vedovato 45, Agostino Consoli 46, Maria Calabrese 47, Paolo di Bartolo 48, Paolo Fornengo 49, Gabriele Riccardi 2; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society
Collaborators, Affiliations
- PMID: 28917544
- DOI: 10.1016/S2213-8587(17)30317-0
Randomized Controlled Trial
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
Olga Vaccaro et al. Lancet Diabetes Endocrinol. 2017 Nov.
Erratum in
- Correction to Lancet Diabetes Endocrinol 2017; 5: 887-97.
[No authors listed] [No authors listed] Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7. doi: 10.1016/S2213-8587(17)30333-9. Lancet Diabetes Endocrinol. 2017. PMID: 29082881 No abstract available.
Abstract
Background: The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes.
Methods: TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50-75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2-3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and previous cardiovascular events, to add-on pioglitazone (15-45 mg) or a sulfonylurea (5-15 mg glibenclamide, 2-6 mg glimepiride, or 30-120 mg gliclazide, in accordance with local practice). The trial was unblinded, but event adjudicators were unaware of treatment assignment. The primary outcome, assessed with a Cox proportional-hazards model, was a composite of first occurrence of all-cause death, non-fatal myocardial infarction, non-fatal stroke, or urgent coronary revascularisation, assessed in the modified intention-to-treat population (all randomly assigned participants with baseline data available and without any protocol violations in relation to inclusion or exclusion criteria). This study is registered with ClinicalTrials.gov, number NCT00700856.
Findings: Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 per 100 person-years) who were given sulfonylureas (hazard ratio 0·96, 95% CI 0·74-1·26, p=0·79). Fewer patients had hypoglycaemias in the pioglitazone group than in the sulfonylureas group (148 [10%] vs 508 [34%], p<0·0001). Moderate weight gain (less than 2 kg, on average) occurred in both groups. Rates of heart failure, bladder cancer, and fractures were not significantly different between treatment groups.
Interpretation: In this long-term, pragmatic trial, incidence of cardiovascular events was similar with sulfonylureas (mostly glimepiride and gliclazide) and pioglitazone as add-on treatments to metformin. Both of these widely available and affordable treatments are suitable options with respect to efficacy and adverse events, although pioglitazone was associated with fewer hypoglycaemia events.
Funding: Italian Medicines Agency, Diabete Ricerca, and Italian Diabetes Society.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Comment in
- Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs.
Fonseca VA, Lovre D. Fonseca VA, et al. Lancet Diabetes Endocrinol. 2017 Nov;5(11):845-847. doi: 10.1016/S2213-8587(17)30320-0. Epub 2017 Sep 13. Lancet Diabetes Endocrinol. 2017. PMID: 28917543 Free PMC article. No abstract available. - Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?
Abdul-Ghani M, Jayyous A, Asaad N, Helmy S, Al-Suwaidi J. Abdul-Ghani M, et al. Ann Transl Med. 2018 May;6(10):192. doi: 10.21037/atm.2018.03.19. Ann Transl Med. 2018. PMID: 29951514 Free PMC article. No abstract available.
Similar articles
- Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). Vaccaro O, et al. Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003. Epub 2012 Oct 11. Nutr Metab Cardiovasc Dis. 2012. PMID: 23063367 Clinical Trial. - Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH. Aroda VR, et al. Lancet Diabetes Endocrinol. 2017 May;5(5):355-366. doi: 10.1016/S2213-8587(17)30085-2. Epub 2017 Mar 23. Lancet Diabetes Endocrinol. 2017. PMID: 28344112 Clinical Trial. - Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP. Plosker GL, et al. Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review. - Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T. Hemmingsen B, et al. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009008. doi: 10.1002/14651858.CD009008.pub2. Cochrane Database Syst Rev. 2013. PMID: 23633364 Updated. Review.
Cited by
- Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review.
Sahin I, Bakiner O, Demir T, Sari R, Atmaca A. Sahin I, et al. Diabetes Ther. 2024 Aug;15(8):1687-1716. doi: 10.1007/s13300-024-01612-8. Epub 2024 Jun 27. Diabetes Ther. 2024. PMID: 38935188 Free PMC article. Review. - Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies.
Genua I, Cusi K. Genua I, et al. Diabetes Spectr. 2024 Winter;37(1):48-58. doi: 10.2337/dsi23-0012. Epub 2024 Feb 15. Diabetes Spectr. 2024. PMID: 38385098 Free PMC article. - Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review.
Sheikh IM, Hassan OA, Adam SM, Ali AI, Ogedegbe OJ, Tabowei G, Barbarawi A, Yussuf FM, Nor MA. Sheikh IM, et al. Cureus. 2023 Oct 12;15(10):e46911. doi: 10.7759/cureus.46911. eCollection 2023 Oct. Cureus. 2023. PMID: 37954768 Free PMC article. Review. - Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer's Disease via Neuroinflammation and Ferroptosis.
Yang J, Shi X, Wang Y, Ma M, Liu H, Wang J, Xu Z. Yang J, et al. J Alzheimers Dis. 2023;96(3):927-945. doi: 10.3233/JAD-230593. J Alzheimers Dis. 2023. PMID: 37927258 Free PMC article. Review. - Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study.
Ragazzi E, Burlina S, Cosma C, Chilelli NC, Lapolla A, Sartore G. Ragazzi E, et al. Front Endocrinol (Lausanne). 2023 Aug 11;14:1163554. doi: 10.3389/fendo.2023.1163554. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37635976 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical